Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2042333
Max Phase: Preclinical
Molecular Formula: C30H48O2
Molecular Weight: 440.71
Molecule Type: Small molecule
Associated Items:
ID: ALA2042333
Max Phase: Preclinical
Molecular Formula: C30H48O2
Molecular Weight: 440.71
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C=C(C=O)[C@@H]1CC[C@]2(C)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12
Standard InChI: InChI=1S/C30H48O2/c1-19(18-31)20-10-13-27(4)16-17-29(6)21(25(20)27)8-9-23-28(5)14-12-24(32)26(2,3)22(28)11-15-30(23,29)7/h18,20-25,32H,1,8-17H2,2-7H3/t20-,21+,22-,23+,24-,25+,27+,28-,29+,30+/m0/s1
Standard InChI Key: RYHMCEZDZZBPAQ-QGTGJCAVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: Yes | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 440.71 | Molecular Weight (Monoisotopic): 440.3654 | AlogP: 7.20 | #Rotatable Bonds: 2 |
Polar Surface Area: 37.30 | Molecular Species: NEUTRAL | HBA: 2 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 2 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 6.48 | CX LogD: 6.48 |
Aromatic Rings: 0 | Heavy Atoms: 32 | QED Weighted: 0.36 | Np Likeness Score: 3.15 |
1. Gutiérrez-Nicolás F, Gordillo-Román B, Oberti JC, Estévez-Braun A, Ravelo AG, Joseph-Nathan P.. (2012) Synthesis and anti-HIV activity of lupane and olean-18-ene derivatives. Absolute configuration of 19,20-epoxylupanes by VCD., 75 (4): [PMID:22462772] [10.1021/np200910u] |
2. Khan MF, Maurya CK, Dev K, Arha D, Rai AK, Tamrakar AK, Maurya R.. (2014) Design and synthesis of lupeol analogues and their glucose uptake stimulatory effect in L6 skeletal muscle cells., 24 (12): [PMID:24813738] [10.1016/j.bmcl.2014.04.059] |
3. Bhandari P, Patel NK, Bhutani KK.. (2014) Synthesis of new heterocyclic lupeol derivatives as nitric oxide and pro-inflammatory cytokine inhibitors., 24 (15): [PMID:24909081] [10.1016/j.bmcl.2014.05.032] |
Source(1):